Evergy Inc. Common Stock vs Cassava Sciences Inc — how do they compare? Evergy Inc. Common Stock trades at $81.8 (market cap $18.52B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Evergy Inc. Common Stock is far larger — about 470.1× Cassava Sciences Inc's market cap, and Evergy Inc. Common Stock pays a 3.46% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Evergy Inc. Common Stock for 0 Days and Cassava Sciences Inc for 37 Days on average.
| EVRG | FLNA | |
|---|---|---|
Market Cap | $18.52B | $39.40M |
Volume | 2,350,243 | 759,018 |
Sector | Utilities | Health |
52-Week High | $88.13 | $4.64 |
52-Week Low | $72.31 | $0.68 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $34.99B | -$43.28M |
Dividend Yield | 3.46% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Evergy is a regulated electric utility serving customers in Kansas and Missouri. Its operations include electricity generation, transmission, and distribution through its integrated utility subsidiaries.
Read more on EVRG →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →